A Phase 3 interventional study of Bexagliflozin tablets, 20 mg and Bexagliflozin tablets, placebo in Type2 Diabetes Mellitus, sponsored by Theracos. Completed at 43 sites in 2 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by Theracos · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetes Mellitus, Type 2 by Theracos — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Theracos.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one is the 4th largest by enrollment, is one of 5 that started in 2017, is one of 6 in phase 3, and was the 14th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 17 studies in Diabetes Mellitus, Type 2 by Theracos is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 351 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 78 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Approximately 300 subjects with inadequately controlled T2DM on metformin were to be recruited from the United States and Japan. Subjects were randomly assigned to receive bexagliflozin tablets, 20 mg, or bexagliflozin tablets, placebo, in a ratio of 1:1 once daily for 24 weeks. Subjects were to continue taking metformin for the duration of the study. The study also enrolled 50 subjects with extremely poorly controlled T2DM on metformin to receive open-label bexagliflozin tablets, 20 mg, for 24 weeks.
The subjects were required to meet the following criteria at the time of enrollment to be eligible for the study:
Subjects who met any of the following criteria were to be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bexagliflozin tablets, 20 mg
Drug: Bexagliflozin tablets, placebo
Drug: Bexagliflozin tablets, 20 mg
Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Also known as: EGT0001442, EGT0001474
Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Also known as: EGT0001442, EGT0001474
Change From Baseline in HbA1c at Week 24 for Double-blind Group
HbA1c was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.
Time frame: Baseline to week 24
Change From Baseline in HbA1c at Week 24 for High Glycemic Group
The change in HbA1c from baseline at Week 24 in High Glycemic Group was calculated by subtracting the mean HbA1c at baseline from the mean HbA1c at Week 24
Time frame: Baseline to week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for Double-blind Group
FPG was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.
Time frame: Baseline, up to 24 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for High Glycemic Group
The change in FPG from baseline at Week 24 for High Glycemic Group was calculated by subtracting the mean FPG at baseline from the mean FPG at Week 24
Time frame: Baseline, up to 24 weeks
Change From Baseline in Systolic Blood Pressure (SBP) at Week 24
Changes from baseline at Week 24 in SBP for the double-blind group and high glycemic group
Time frame: Baseline to week 24
Proportion of Subjects Achieving HbA1c < 7% Over Time for Double-blind Group
The proportion of subjects who achieved HbA1c \< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group. The model-adjusted proportion was calculated based on a logistic analysis using Generalized Estimating Equation (GEE) logistic regression that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate. An unstructured correlation structure will be used, or autoregressive if the model with the unstructured structure does not converge.
Time frame: Baseline, up to 24 weeks
Proportion of Subjects Achieving HbA1c < 7% Over Time for High Glycemic Group
The proportion of subjects who achieved HbA1c \< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group.
Time frame: Baseline, up to 24 weeks
Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for Double-blind Group
Changes in body mass from baseline to week 24 was calculated based on LS means for both bexagliflozin and placebo groups.
Time frame: Baseline to week 24
Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for High Glycemic Group
The change in body mass from baseline at week 24 for High Glycemic group was calculated by subtracting the mean body mass at baseline from the mean body mass at week 24
Time frame: Baseline to week 24
Change From Baseline in HbA1c Over Time in Double-blind Treatment Group
The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point for each group. The model-adjusted change from baseline was calculated based on a mixed-effects repeated measures analysis that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate.
Time frame: Baseline, up to 24 weeks
Change in HbA1c Over Time Among Subjects Who Have Baseline HbA1c of > 10.5% and ≤ 12.0%
The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point in High Glycemic Group.
Time frame: Baseline, up to 24 weeks
| Milestone | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group |
|---|---|---|---|
| Started | 158 | 159 | 34 |
| Completed | 141 | 142 | 28 |
| Not completed | 17 | 17 | 6 |
| Withdrew: Adverse event | 3 | 2 | 1 |
| Withdrew: Withdrawal by subject | 9 | 5 | 1 |
| Withdrew: Lost to follow-up | 5 | 9 | 4 |
| Withdrew: Physician decision | 0 | 1 | 0 |
HbA1c was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.
| percentage of HbA1c | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo |
|---|---|---|
| Change From Baseline in HbA1c at Week 24 for Double-blind Group | -1.09 ± 0.076 | -0.56 ± 0.075 |
The change in HbA1c from baseline at Week 24 in High Glycemic Group was calculated by subtracting the mean HbA1c at baseline from the mean HbA1c at Week 24
| percentage of HbA1c | High Glycemic Group |
|---|---|
| Change From Baseline in HbA1c at Week 24 for High Glycemic Group | -2.82 ± 1.084 |
FPG was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.
| mmol/L | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for Double-blind Group | -2.51 ± 0.174 | -1.16 ± 0.173 |
The change in FPG from baseline at Week 24 for High Glycemic Group was calculated by subtracting the mean FPG at baseline from the mean FPG at Week 24
| mmol/L | High Glycemic Group |
|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for High Glycemic Group | -4.98 ± 3.437 |
Changes from baseline at Week 24 in SBP for the double-blind group and high glycemic group
| mm Hg | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 24 | -5.03 ± 0.993 | 2.04 ± 0.987 | -8.19 ± 14.882 |
The proportion of subjects who achieved HbA1c \< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group. The model-adjusted proportion was calculated based on a logistic analysis using Generalized Estimating Equation (GEE) logistic regression that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate. An unstructured correlation structure will be used, or autoregressive if the model with the unstructured structure does not converge.
| Proportion of subjects | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo |
|---|---|---|
| Week 6 | 0.14 (0.09 to 0.23) | 0.03 (0.01 to 0.07) |
| Week 12 | 0.26 (0.18 to 0.38) | 0.06 (0.03 to 0.12) |
| Week 18 | 0.26 (0.18 to 0.39) | 0.10 (0.06 to 0.18) |
| Week 24 | 0.38 (0.26 to 0.55) | 0.10 (0.06 to 0.17) |
The proportion of subjects who achieved HbA1c \< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group.
| Proportion of subjects | High Glycemic Group |
|---|---|
| Week 6 | 0 |
| Week 12 | 0.065 |
| Week 18 | 0.097 |
| Week 24 | 0.138 |
Changes in body mass from baseline to week 24 was calculated based on LS means for both bexagliflozin and placebo groups.
| kg | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo |
|---|---|---|
| Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for Double-blind Group | -3.60 ± 0.348 | -1.09 ± 0.336 |
The change in body mass from baseline at week 24 for High Glycemic group was calculated by subtracting the mean body mass at baseline from the mean body mass at week 24
| kg | High Glycemic Group |
|---|---|
| Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for High Glycemic Group | -1.40 ± 3.759 |
The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point for each group. The model-adjusted change from baseline was calculated based on a mixed-effects repeated measures analysis that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate.
| percentage of HbA1c | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo |
|---|---|---|
| Week 6 | -0.72 ± 0.065 | -0.16 ± 0.065 |
| Week 12 | -0.97 ± 0.073 | -0.31 ± 0.073 |
| Week 18 | -1.00 ± 0.072 | -0.51 ± 0.072 |
| Week 24 | -1.09 ± 0.076 | -0.56 ± 0.075 |
The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point in High Glycemic Group.
| percentage of HbA1c | High Glycemic Group |
|---|---|
| Week 6 | -1.72 ± 1.027 |
| Week 12 | -2.45 ± 1.136 |
| Week 18 | -2.62 ± 1.055 |
| Week 24 | -2.82 ± 1.084 |
Collected over Adverse events were collected from Week -1 (run in period: Visit 2) to Week 26 (Follow up: Visit 8).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Group: Bexagliflozin 20 mg | 0/158 (0%) | 3/158 (1.9%) | 16/158 (10.1%) |
| Double-blind Group: Placebo | 0/159 (0%) | 4/159 (2.5%) | 28/159 (17.6%) |
| High Glycemic Group | 0/34 (0%) | 0/34 (0%) | 7/34 (20.6%) |
| Event | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group |
|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/158 | 0/159 | 0/34 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/158 | 0/159 | 0/34 |
| Acute cardiac failureCardiac disorders | 1/158 | 0/159 | 0/34 |
| Atrial fibrillationCardiac disorders | 0/158 | 1/159 | 0/34 |
| ConstipationGastrointestinal disorders | 0/158 | 1/159 | 0/34 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/158 | 1/159 | 0/34 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/158 | 1/159 | 0/34 |
| HypertensionVascular disorders | 0/158 | 1/159 | 0/34 |
| Event | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group |
|---|---|---|---|
| PolyuriaRenal and urinary disorders | 5/158 | 6/159 | 4/34 |
| PolydipsiaMetabolism and nutrition disorders | 5/158 | 4/159 | 3/34 |
| NasopharyngitisInfections and infestations | 9/158 | 13/159 | 1/34 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 3/158 | 10/159 | 1/34 |
| Glomerular filtration rate decreasedInvestigations | 0/158 | 0/159 | 2/34 |
| Age, Continuous(years) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Double-blind Group | 56.0 ± 10.05 | 55.6 ± 11.18 | — | 55.8 ± 10.62 |
| High Glycemic Group | — | — | 52.1 ± 8.59 | 52.1 ± 8.59 |
| Sex: Female, Male(Participants) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Female | 58 | 65 | 15 | 138 |
| Male | 100 | 94 | 19 | 213 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Hispanic or Latino | 35 | 32 | 9 | 76 |
| Not Hispanic or Latino | 123 | 127 | 25 | 275 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 3 |
| Asian | 78 | 79 | 9 | 166 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 26 | 29 | 12 | 67 |
| White | 51 | 48 | 11 | 110 |
| More than one race | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| United States | 83 | 83 | 27 | 193 |
| Japan | 75 | 76 | 7 | 158 |
| Height(cm) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Double-blind Group | 168.4 ± 9.71 | 167.3 ± 9.55 | — | 167.8 ± 9.63 |
| High Glycemic Group | — | — | 169.4 ± 9.34 | 169.4 ± 9.34 |
| Body Weight(kg) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Double-blind Group | 84.58 ± 21.989 | 84.44 ± 20.928 | — | 84.51 ± 21.43 |
| High Glycemic Group | — | — | 87.28 ± 17.759 | 87.28 ± 17.759 |
| BMI(kg/m^2) | Double-blind Group: Bexagliflozin 20 mg | Double-blind Group: Placebo | High Glycemic Group | Total |
|---|---|---|---|---|
| Double-blind Group | 29.67 ± 6.45 | 29.99 ± 6.342 | — | 29.83 ± 6.388 |
| High Glycemic Group | — | — | 30.37 ± 5.558 | 30.37 ± 5.558 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Jan 2019, 13 months.
Results were first posted in Jul 2021, 2 years 5 months after primary completion. A results delay was requested in Jan 2019.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theracos